172 results on '"Kizilbash, Sani H."'
Search Results
2. Methodological and analytical considerations for intra-operative microdialysis
3. An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence
4. Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
5. Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis
6. The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study
7. Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma
8. Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
9. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study
10. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience
11. Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design
12. MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma
13. The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database
14. NIMG-57. PERFORMANCE OF DEEP LEARNING IN MGMT PROMOTER METHYLATION STATUS PREDICTION USING BRAIN MRI: RESULTS FROM A LARGE COHORT OF IDH-WILDTYPE GLIOMAS TESTED BY A SINGLE METHYLATION ASSAY
15. CTIM-33. EFFICACY AND SAFETY STUDY OF NEOADJUVANT EFINEPTAKIN ALFA (NT-I7) AND PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA
16. EXTH-37. FUNCTIONAL GENOMICS IDENTIFIES THERAPEUTIC VULNERABILITIES OF GLIOMA SUBTYPES AND YAP/TAZ-ENRICHED TUMORS
17. RADT-18. PROTON CRANIOSPINAL IRRADIATION WITH CHECKPOINT INHIBITOR THERAPY FOR PATIENTS WITH LEPTOMENINGEAL DISEASE FROM SOLID TUMORS – A SINGLE INSTITUTION CASE SERIES
18. NCOG-18. CLINICAL CHARACTERISTICS OF H3.G34 DIFFUSE HEMISPHERIC GLIOMA: A CASE SERIES AND REVIEW OF THE LITERATURE
19. CTNI-53. ESTABLISHING A PHASE I AND RANDOMIZED PHASE II TRIAL OF SELINEXOR AND TEMOZOLOMIDE IN GLIOBLASTOMA
20. CTNI-03. EFFICACY OF WSD0922-FU IN OSIMERTINIB-RESISTANT NSCLC WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES – UPDATES FROM THE DOSE ESCALATION COHORT OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
21. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
22. Management and Long-term Outcomes of Adults With Medulloblastoma
23. Treatment outcome of metastasis to the pituitary gland: a case series of 21 patients with pathological diagnosis
24. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
25. Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High–Molecular Weight Microdialysis
26. Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors
27. Figure S1 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
28. Data from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
29. Supplementary Information from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
30. Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
31. Contemporary Treatment Outcome of Metastases to the Pituitary Gland
32. Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
33. Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas
34. Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
35. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
36. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine
37. Seizures in patients with primary brain tumors: what is their psychosocial impact?
38. Why has targeting EGFR aberrations in glioblastoma therapy had limited success?
39. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
40. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
41. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma
42. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma
43. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
44. Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
45. Does Blood-Brain Barrier Disruption Define the Glioma Extracellular Metabolome?
46. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
47. Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.
48. Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity
49. Efficacy of 177Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
50. Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.